Nucleic Acid Synthesis Inhibitors

Nucleoside Metabolic Inhibitor

Anemia, Refractory

Anemia, Sideroblastic

Leukemia, Myelomonocytic, Chronic

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Azacitidine is a nucleoside metabolic inhibitor with a molecular formula of C<span class="Sub">8</span>H<span class="Sub">12</span>N<span class="Sub">4</span>O<span class="Sub">5</span> and a molecular weight of 244 g/mol. The chemical name is: 4-amino-1-β-D-ribofuranosyl-s-triazin-2(1H)-one and the chemical structural is:</p><div class="Figure"><a name="id1238"></a><img alt="onureg-chem-structure" src="onureg-chem-structure.jpg"/></div><p>Azacitidine is a white to off-white solid. Azacitidine was found to be soluble in aqueous media across a pH range from 1.0 to 7.0.</p><p>ONUREG (azacitidine) is supplied as film-coated tablets containing 200 mg or 300 mg of azacitidine for oral use. Each core tablet contains the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and silicified microcrystalline cellulose. The 200 and 300 mg tablet coating contains hypromellose, lactose monohydrate, polyethylene glycol, titanium dioxide, and triacetin. In addition, the 200 mg tablet coating contains iron oxide red and the 300 mg tablet coating contains black iron oxide, iron oxide red, and iron oxide yellow.</p></section>

ONUREG

azacitidine

azacitidine 200 MG Oral Tablet

Onureg

azacitidine 200 MG Oral Tablet [Onureg]

azacitidine 300 MG Oral Tablet

azacitidine 300 MG Oral Tablet [Onureg]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

How To Order Onureg

Billing & Coding Guide 

Formulary Information

Reimbursement Information

Onureg Enrollment Form 

Onureg Enrollment Form - Spanish

Coverage Authorization Request 

Coverage Authorization Appeals 

Commercial Claim Denial Appeal/Redetermination Letter

Medically Unlikely Edit (MUE) Appeal Letter

Letter of Medical Necessity 

Other HCP Resources - Forms 

My BMS Cases: Access Online Portal 

Enroll in Patient Savings Program 

Other HCP Resources 

About Onureg

Taking Onureg

Side Effects 

Patient Resources

Doctor Discussion Guide

Patient Brochure 

Instructions For Use: AML 

Managing Side Effects

Checklist For Taking Onureg